Omega-3 Supplements May Lower Anxiety

Subjects randomized to receive omega-3 supplements had greater decreases in anxiety and inflammation than those receiving placebo. Medscape Medical News

‘Explosion’ of Sex-Spread Hepatitis C in HIV-Positive Men

Hepatitis C from high-risk sex is ‘widespread’ in U.S., Europe, and Australia. WebMD Health News

Readers Split on Removing Obese Kids from Their Homes

(MedPage Today) — More than half of the respondents to a MedPage Today poll think that morbidly obese children should be removed from their parents’ custody, although most of those who do said that such a change should occur only in “extreme cases.”

Hep C Virus Transmitted in Risky Gay Sex (CME/CE)

(MedPage Today) — Sexual transmission of hepatitis C virus appears to be on the rise among HIV-infected men who have sex with men, according to the CDC.

Group Calls for Improvements in Home Healthcare

WASHINGTON (MedPage Today) — The National Resource Council has called for medical groups and government agencies to work together to ensure that people who provide home healthcare are well-trained and that medical devices used in the home are easy for laypeople to use.

22nd Century receives FDA approval for X-22 IND to conduct Phase II-B smoking cessation trial

22nd Century Group, Inc., a company focused on smoking cessation and tobacco harm reduction products, today announced that the U.S. Food & Drug Administration (FDA) has cleared an Investigational New Drug (IND) Application to conduct a Phase II-B clinical trial using X-22, a prescription smoking cessation aid in development.

Enrollment begins in Repligen’s RG1068 pilot study to improve detection, staging of pancreatic cancer

Repligen Corporation today announced that the first patient has been enrolled in a pilot study to evaluate the ability of RG1068 to improve detection and characterization of pancreatic cancer in combination with contrast-enhanced magnetic resonance imaging (MRI) and computed tomography.

UK regulators approve Europe’s first clinical trial of plant-derived antibody for HIV

UK regulators have approved Europe’s first clinical trial of a monoclonal antibody produced from genetically modified plants. This landmark decision sets the stage for the testing, in humans, of an anti-HIV product made from genetically modified tobacco plants. It will open the door for trials of additional plant-derived medicines treating a range of diseases.

Taiho announces results of TAS-102 Phase II trial for metastatic colorectal cancer

Taiho Pharmaceutical Co., Ltd. announced on July 22 the results of a randomized, Phase II clinical trial for the novel oral nucleoside antitumor agent TAS-102 under development by the company for metastatic colorectal cancer, at the 9th Annual Meeting of the Japanese Society of Medical Oncology held in Yokohama.

Inotek completes two stages of INO-8875 Phase 2b trial against glaucoma

Inotek Pharmaceuticals Corp., a leader in the development of innovative medicines to address significant diseases of the eye, today announced that the Company has successfully completed the first two of three stages of a multiple-dose Phase 2b clinical trial of its novel eye-drop candidate, INO-8875, in patients with glaucoma or ocular hypertension.